Literature DB >> 9874695

Pharmacokinetic considerations in obesity.

R A Blouin1, G W Warren.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 9874695     DOI： 10.1021/js980173a

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  44 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 3.  Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.

Authors:  Neil S Horowitz; Alexi A Wright
Journal:  Gynecol Oncol       Date:  2015-04-12       Impact factor: 5.482

4.  Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters.

Authors:  Romi Ghose; Ozozoma Omoluabi; Adarsh Gandhi; Pranav Shah; Kelley Strohacker; Katie C Carpenter; Brian McFarlin; Tao Guo
Journal:  Life Sci       Date:  2011-05-18       Impact factor: 5.037

5.  Anesthesia for bariatric surgery.

Authors:  Tomoki Nishiyama; Yumiko Kohno; Keiko Koishi
Journal:  Obes Surg       Date:  2012-02       Impact factor: 4.129

6.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

Review 7.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

8.  Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

Authors:  Aaron M Cook; Craig Martin; Val R Adams; R Scott Morehead
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 9.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 10.  Appendicitis in obese children.

Authors:  Balazs Kutasy; Prem Puri
Journal:  Pediatr Surg Int       Date:  2013-03-10       Impact factor: 1.827
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.